Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorDongying Zhang
About this trial
Heart failure (HF) is a severe cardiovascular disease with extremely high morbidity and mortality rates worldwide, and ischemic cardiomyopathy is an important cause of heart failure. Vericiguat is a soluble guanylate cyclase stimulator which has been verified to improve the cardiovascular outcomes in heart failure patients. The VICTORIA trial excluded patients with acute coronary syndrome in 3 months prior to the study start, so it is still unclear about the efficacy and safety of vericiguat in heart failure after acute myocardial infarction. So we conducted this multi-center, prospective, cohort study to estimate the efficacy and safety of vericiguat in HF patients after acute myocardial infarction.
Eligibility criteria
Qualifiers
Age ≥ 18 years old
Undertaking revascularization for criminal coronary artery during hospitalization
Acute heart failure occurs within 14 days in hospital after STEMI or NSTEMI, meeting all of the following criteria: typical symptoms or signs of heart failure; Treatment with oral or intravenous diuretics is required; LVEF measured by echocardiography is ≤ 45%; Elevated levels of NT proBNP in patients with sinus rhythm ≥ 1000pg/ml and atrial fibrillation/flutter ≥ 1600pg/ml
eGFR ≥ 15 ml/min/1.73m2
Disqualifiers
Plan to undergo staged revascularization or if the criminal coronary artery has not been successfully opened
Severe and uncontrolled lung diseases, such as newly developed pulmonary embolism, primary pulmonary hypertension, acute exacerbation of COPD, etc
Severe liver and kidney dysfunction, Child Pugh grade C or eGFR < 15ml/min/1.73m2
Allergies to ACEI, ARB, ARNI, beta blockers, SGLT2i, MRA, Vericiguat, and other medications
Trial design
Treatments tested in this trial
- Vericiguat
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Dongying Zhang
Lead sponsor
Chongqing Emergency Medical Center
Sponsor institution
The Second Affiliated Hospital of Chongqing Medical University
Collaborator
The First Affiliated Hospital of Chongqing Medical Universty
Collaborator
Source ClinicalTrials.gov